Attainable predictive biomarkers for tumor response to mTOR inhibitors, as are already explained in glioblastoma, breast and prostate most cancers cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Therefore, this info relies on preclinical assays, based on in vitro cultured tumor cell lines, which https://christophern776jbu8.blue-blogs.com/profile